Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03488667 · ClinicalTrials.gov registry record · Phase 2
Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach Adenocarcinoma
A Phase 2 study of Adenocarcinoma and Gastroesophageal-junction Cancer, sponsored by University of Kansas Medical Center.
- Active
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT03488667: Active Phase 2 study of Adenocarcinoma and Gastroesophageal-junction Cancer, sponsored by University of Kansas Medical Center.
NCT03488667 is a Phase 2 study of Adenocarcinoma and Gastroesophageal-junction Cancer that is active but no longer recruiting, run by University of Kansas Medical Center. The registered enrollment target is 40 participants, below the 95-participant average among 26 other Adenocarcinoma trials with a reported enrollment target (58% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03488667, a Phase 2 study of Adenocarcinoma and Gastroesophageal-junction Cancer, is active but no longer recruiting, sponsored by University of Kansas Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
To evaluate the antitumor activity and safety/tolerability of the combination (mFOLFOX + Pembrolizumab) in patients with potentially resectable adenocarcinoma of the Gastroesophageal Junction (GEJ) and stomach.
Primary Outcome
Number of participants with ypRR after neoadjuvant therapy. Will be assessed on the surgical resection specimen after neoadjuvant therapy, using Haemotoxylin and Eosin (H\&E) staining and evaluated using Tumor Regression Score.
Conditions Studied
Interventions
- DRUG Neoadjuvant Treatment - mFOLFOX6 & Pembrolizumab
- DRUG Adjuvant Treatment - mFOLFOX & Pembrolizumab
Study Locations (1)
Kansas
- The University of Kansas Cancer Center - Westwood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2018-06-27 |
| Est. Completion | 2025-04-30 |
| Phase | Phase 2 |
What the registry record for NCT03488667 still lists
NCT03488667 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 95-participant average among 26 other Adenocarcinoma trials with a reported enrollment target (58% lower).
The record links to 3 conditions, with Adenocarcinoma appearing as the primary indexed condition, and to 2 interventions - of which Neoadjuvant Treatment - mFOLFOX6 & Pembrolizumab is the first listed.
NCT03488667 reports a single indexed study location in Kansas.
Frequently Asked Questions
What is clinical trial NCT03488667 about?
NCT03488667 is a clinical study titled "Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach Adenocarcinoma". To evaluate the antitumor activity and safety/tolerability of the combination (mFOLFOX + Pembrolizumab) in patients with potentially resectable adenocarcinoma of the Gastroesophageal Junction (GEJ) and stomach.
What is the current status of trial NCT03488667?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2018-06-27. Estimated completion is 2025-04-30.
What conditions does trial NCT03488667 study?
This clinical trial studies the following conditions: Adenocarcinoma, Gastroesophageal-junction Cancer, Stomach Cancer.
What interventions are being tested in trial NCT03488667?
The interventions under investigation include: Neoadjuvant Treatment - mFOLFOX6 & Pembrolizumab (DRUG), Adjuvant Treatment - mFOLFOX & Pembrolizumab (DRUG).
Who is sponsoring clinical trial NCT03488667?
This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03488667 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03488667's enrollment target sits among peer trials
40 16th of 26 higher than 11 of 26 other Adenocarcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Adenocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
RECRUITING · Phase 2
-
Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma
RECRUITING · Phase 2
-
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
RECRUITING · Phase 2
-
Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma
RECRUITING · Phase 2
-
Erlotinib in Women With Previously Untreated Adenocarcinoma of the Lung
COMPLETED · Phase 2
-
Phase II Trial of Sunitinib in BAC or Never-Smokers With Any Lung Adenocarcinoma
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI